GPT and metabolic dysfunction-associated steatotic liver disease: We anticipate that this synbiotic combination will perform similarly well in clinical trials, serving as a dietary aid to control patients’ weight, reduce blood glucose, lipid, ALT, and AST levels, improve liver damage, and promote overall health in NAFLD patients, and individuals with metabolism-related diseases.